PeptideNerds

Semaglutide vs Tirzepatide vs Retatrutide: Complete GLP-1 Comparison

The ultimate GLP-1 comparison: semaglutide (single), tirzepatide (dual), and retatrutide (triple agonist). Weight loss data, mechanisms, availability, and cost.

DimensionsemaglutidetirzepatideretatrutideNotes
Weight Loss15-17%20-26%24-26%Progressive improvement from single to triple agonist. Retatrutide Phase 2 data rivals tirzepatide.
ReceptorsGLP-1GLP-1 + GIPGLP-1 + GIP + GlucagonEach generation adds a receptor. More receptors = more metabolic pathways activated.
FDA StatusApprovedApprovedPhase 3Semaglutide and tirzepatide available now. Retatrutide expected 2026-2027.
Safety DataExtensiveGrowingLimitedSafety confidence inversely correlated with novelty. Semaglutide has most post-market data.
Cost (Brand)$1,000+/mo$1,000+/moN/ABrand-name GLP-1s are expensive. Retatrutide not yet commercially available.

Weekly peptide research updates

New studies, GLP-1 news, protocol insights, and weight loss data — delivered every week. Free. No spam.

FM

Reviewed by Fat Man in the Arena · Updated March 2026

Medical Disclaimer: This comparison is for informational purposes only. Individual responses vary. Always consult a qualified healthcare provider before starting any peptide protocol.